Conmed (CNMD) Misses Q2 EPS by 8c, Maintains FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Northland Capital Markets Downgrades CONMED (CNMD) to Market Perform
July 22, 2015 7:19 AM EDTNorthland Capital Markets downgraded CONMED (NASDAQ: CNMD) from Outperform to Market Perform with a price target of $58.00 (from $65.00), saying 2nd-half guidance may be too optimistic.
Analyst Mark Landy commented, "CNMD reported in line 2Q revenues of $181M but missed our and the... More
Needham & Company Raises Price Target to $60 Following Conmed's (CNMD) 2Q Miss
July 22, 2015 6:58 AM EDTNeedham & Company reiterated a Buy rating on CONMED (NASDAQ: CNMD), and raised the price target to $60.00 (from $56.00), following 2Q15. CNMD's reported revenue was $181.0M vs. consensus of $182.3M. EPS was $0.36 vs. consensus of $0.44. Analyst Mike Matson said that investors may give management the benefit of... More
